Hemispherx BioPharma Company Profile (NYSE:HEB)

About Hemispherx BioPharma

Hemispherx BioPharma logoHemispherx Biopharma, Inc. (Hemispherx) is a specialty pharmaceutical company. The Company is engaged in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. The Company's segment is engaged in research and development activities related to Ampligen and other drugs under development, and sales and marketing of Alferon. The Company's products include Alferon N Injection and Ampligen. Alferon N Injection is approved for the use in intralesional treatment of refractory or recurring external genital warts in patients of over 18 years of age. Ampligen is a drug undergoing clinical development for the treatment of Chronic Fatigue Syndrome (CFS). Alferon LDO (Low Dose Oral Interferon Alfa-n3 (Human Leukocyte Derived)) is a low-dose, oral liquid formulation of natural alpha interferon. Alferon LDO is a liquid natural interferon for oral administration.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: NYSE
  • Symbol: HEB
  • CUSIP:
Key Metrics:
  • Previous Close: $0.49
  • 50 Day Moving Average: $0.591
  • 200 Day Moving Average: $0.988
  • 52-Week Range: $0.39 - $2.64
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -15.83
  • P/E Growth: 0.000
  • Market Cap: $11.93M
  • Outstanding Shares: 24,105,000
Additional Links:
Companies Related to Hemispherx BioPharma:

Analyst Ratings

Consensus Ratings for Hemispherx BioPharma (NYSE:HEB) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Hemispherx BioPharma (NYSE:HEB)
Show:
DateFirmActionRatingPrice TargetDetails
4/2/2015Midtown PartnersInitiated CoverageStrong-Buy$1.45View Rating Details
(Data available from 3/1/2015 forward)

Earnings

Earnings History for Hemispherx BioPharma (NYSE:HEB)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/27/2017        
11/14/2016Q3 16($0.30)ViewN/AView Earnings Details
8/15/2016Q216($0.01)ViewN/AView Earnings Details
5/16/2016Q116($0.01)$40.99 millionViewN/AView Earnings Details
8/13/2015Q2($0.02)ViewN/AView Earnings Details
5/13/2015Q1 15($0.02)ViewN/AView Earnings Details
8/9/2013Q2 2013($0.03)ViewN/AView Earnings Details
11/5/2012Q312($0.04)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Hemispherx BioPharma (NYSE:HEB)
Current Year EPS Consensus Estimate: $0.000 EPS
Next Year EPS Consensus Estimate: $-0.030 EPS

Dividends

Dividend History for Hemispherx BioPharma (NYSE:HEB)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Hemispherx BioPharma (NYSE:HEB)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/16/2017Adam PascaleCFOBuy6,981$0.46$3,211.26View SEC Filing  
2/16/2017David R StrayerInsiderBuy9,892$0.46$4,550.32View SEC Filing  
2/16/2017Wayne S SpringateSVPBuy8,014$0.46$3,686.44View SEC Filing  
12/22/2016Thomas K EquelsCEOBuy68,493$0.73$49,999.89View SEC Filing  
11/1/2016Thomas K EquelsCEOBuy10,000$1.00$10,000.00View SEC Filing  
7/8/2016Thomas K EquelsCEOBuy48,000$0.12$5,760.00View SEC Filing  
7/1/2016Thomas K EquelsCEOBuy171,000$0.12$20,520.00View SEC Filing  
3/18/2016Thomas K EquelsCEOBuy30,000$0.13$3,900.00View SEC Filing  
3/11/2016Thomas K EquelsCEOBuy40,000$0.16$6,400.00View SEC Filing  
3/10/2016Thomas K EquelsCEOBuy30,000$0.16$4,800.00View SEC Filing  
8/20/2015William A CarterCEOBuy25,000$0.18$4,500.00View SEC Filing  
8/18/2015William A CarterCEOBuy25,000$0.18$4,500.00View SEC Filing  
8/17/2015William A CarterCEOBuy25,000$0.18$4,500.00View SEC Filing  
8/14/2015Thomas K EquelsCFOBuy79,104$0.18$14,238.72View SEC Filing  
4/28/2015William A CarterCEOBuy100,000$0.24$24,000.00View SEC Filing  
4/27/2015Thomas K EquelsCFOBuy100,000$0.24$24,000.00View SEC Filing  
4/21/2015William A CarterCEOBuy100,000$0.24$24,000.00View SEC Filing  
4/20/2015Thomas K EquelsCFOBuy100,000$0.24$24,000.00View SEC Filing  
4/17/2015William A CarterCEOBuy73,681$0.23$16,946.63View SEC Filing  
4/16/2015William A CarterCEOBuy26,319$0.23$6,053.37View SEC Filing  
4/15/2015Thomas K EquelsCFOBuy100,000$0.23$23,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Hemispherx BioPharma (NYSE:HEB)
DateHeadline
News IconBUYINS.NET: HEB, SCSS, WFBI, Expected to Trade Higher After ... - MENAFN.COM (NYSE:HEB)
menafn.com - February 27 at 6:57 PM
News IconThe CAO of Hemispherx Biopharma (NYSE MKT: HEB) is Buying Shares - Analyst Ratings (NYSE:HEB)
www.analystratings.com - February 23 at 5:39 PM
News IconPrice Target Updates on Hemispherx Biopharma, Inc. (:HEB) Spartan Motors, Inc. (NASDAQ:SPAR) - Rives Journal (NYSE:HEB)
rivesjournal.com - February 23 at 5:39 PM
marketexclusive.com logoInsider Trading Activity Hemispherx BioPharma, Inc (NYSE:HEB) – Insider Bought 9,892 shares of Stock (NYSE:HEB)
marketexclusive.com - February 23 at 2:16 AM
4-traders.com logoInsider Trading Activity Hemispherx BioPharma, Inc (NYSE:HEB) – SVP Bought 8,014 shares of Stock (NYSE:HEB)
www.4-traders.com - February 22 at 12:54 PM
marketexclusive.com logoInsider Trading Activity Hemispherx BioPharma, Inc (NYSE:HEB) – CFO Bought 6,981 shares of Stock (NYSE:HEB)
marketexclusive.com - February 22 at 12:54 PM
News IconInvesting Focus: Indicators in View on Shares of Hemispherx Biopharma Inc. (HEB) - Rives Journal (NYSE:HEB)
rivesjournal.com - February 13 at 11:38 PM
News IconHemispherx Biopharma, Inc. (:HEB) Losing Traction Rapidly - Aiken Advocate (NYSE:HEB)
aikenadvocate.com - February 13 at 11:38 PM
News IconStock Watch: Viewing the Numbers for Hemispherx Biopharma Inc. (HEB) - Rives Journal (NYSE:HEB)
rivesjournal.com - February 8 at 11:16 PM
News IconThe FY2016 EPS Estimates for Sarepta Therapeutics, Inc. Increased by Analyst (SRPT) (NYSE:HEB)
mlbinjurynews.com - February 7 at 6:57 PM
News IconHemispherx BioPharma, Inc. (AMEX:HEB) Quarterly Analytical Analysis - The Newburgh Press (NYSE:HEB)
newburghpress.com - February 5 at 5:24 PM
News IconBreaking Down The Hemispherx BioPharma, Inc (NYSEMKT:HEB) Catalsysts - Insider Financial (NYSE:HEB)
www.insiderfinancial.com - February 5 at 5:24 PM
marketexclusive.com logoHEMISPHERX BIOPHARMA, INC. (NYSEMKT:HEB) Files An 8-K Entry into a Material Definitive Agreement (NYSE:HEB)
marketexclusive.com - February 3 at 6:08 PM
bizjournals.com logo$1M deal: Hemispherx plans to sell stock, warrants (NYSE:HEB)
www.bizjournals.com - February 3 at 6:08 PM
us.rd.yahoo.com logoHemispherx Biopharma, Inc. Announces $1 Million Registered Direct Offering (NYSE:HEB)
us.rd.yahoo.com - February 2 at 6:15 PM
us.rd.yahoo.com logo8:31 am Hemispherx Biopharma announces $1 mln registered direct offering at $0.55/share (NYSE:HEB)
us.rd.yahoo.com - February 2 at 6:15 PM
News IconNarrowing in on Trading Indicators for Hemispherx Biopharma Inc. (HEB) - Sherwood Daily (NYSE:HEB)
sherwooddaily.com - January 30 at 11:25 PM
News IconAre Insiders Bumping Up Their Positions in Hemispherx Biopharma, Inc. (:HEB) - Wall Street Beacon (NYSE:HEB)
wsbeacon.com - January 30 at 11:32 AM
News IconOff To a Slow Start in The New Year, Stock Looks For a Turnaround: Hemispherx Biopharma, Inc. (:HEB) - Aiken Advocate (NYSE:HEB)
aikenadvocate.com - January 28 at 10:49 PM
News IconIndicator Level Summary for Hemispherx Biopharma Inc. (HEB) - Sherwood Daily (NYSE:HEB)
sherwooddaily.com - January 27 at 7:35 PM
News IconInvestor Corner: Checking in on Shares of Hemispherx Biopharma Inc. (HEB) - Sherwood Daily (NYSE:HEB)
sherwooddaily.com - January 26 at 7:11 PM
News IconIs This Equity Ready for a Breakout: Hemispherx Biopharma, Inc. (:HEB) - Prospect Journal (NYSE:HEB)
prospectjournal.com - January 26 at 7:11 PM
smarteranalyst.com logoStock Update (NYSE MKT:HEB): Hemispherx BioPharma, Inc Announces First Shipment of Newly Manufactured ... - Smarter Analyst (NYSE:HEB)
www.smarteranalyst.com - January 26 at 7:11 PM
finance.yahoo.com logoHemispherx Announces First Shipment of Newly Manufactured Rintatolimod (Ampligen®) for Sale to Early Access Program in Europe (NYSE:HEB)
finance.yahoo.com - January 26 at 7:11 PM
finance.yahoo.com logo10:52 am Hemispherx Biopharma announces an order of newly manufactured rintatolimod (Ampligen) for sale utilizing the Early Access Program in Europe has been shipped with receipt confirmed on January 26 (NYSE:HEB)
finance.yahoo.com - January 26 at 7:11 PM
News IconCan This Stock Pick Up Any Momentum: Hemispherx Biopharma, Inc. (:HEB) - Prospect Journal (NYSE:HEB)
prospectjournal.com - January 26 at 5:02 AM
News IconInvestors are Looking at Levels for Hemispherx Biopharma Inc. (HEB) - Sherwood Daily (NYSE:HEB)
sherwooddaily.com - January 20 at 11:59 PM
News IconPeculiar Activity & Volume Spotted in Shares of Hemispherx Biopharma, Inc. (:HEB) - Aiken Advocate (NYSE:HEB)
aikenadvocate.com - January 20 at 11:59 PM
News IconIs This Stock Ready to Rumble: Hemispherx Biopharma, Inc. (:HEB) - Prospect Journal (NYSE:HEB)
prospectjournal.com - January 20 at 11:59 PM
4-traders.com logoHEMISPHERX BIOPHARMA INC : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K) (NYSE:HEB)
www.4-traders.com - January 18 at 6:06 PM
News IconPlacing This Stock in the Hotbed: Hemispherx Biopharma, Inc. (:HEB) - Prospect Journal (NYSE:HEB)
prospectjournal.com - January 17 at 8:40 PM
biz.yahoo.com logoHEMISPHERX BIOPHARMA INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exh (NYSE:HEB)
biz.yahoo.com - January 17 at 8:40 PM
News IconSpot-check on CCI and RSI for Hemispherx Biopharma Inc. (HEB) - Sherwood Daily (NYSE:HEB)
sherwooddaily.com - January 17 at 3:39 PM
News IconVolume Out of Kilter As Stock Experiences Unusual Activity: Hemispherx Biopharma, Inc. (:HEB) - Aiken Advocate (NYSE:HEB)
aikenadvocate.com - January 17 at 3:39 PM
News IconHemispherx BioPharma, Inc (HEB) Spikes On Extension Of Rintatolimod European EAP To Pancreatic Cancer (NYSE:HEB)
feedproxy.google.com - January 15 at 3:28 PM
News IconMarkets End Mostly Higher, How Did This Stock Fare: Hemispherx Biopharma, Inc. (:HEB) - Wall Street Beacon (NYSE:HEB)
wsbeacon.com - January 14 at 10:42 PM
kcregister.com logoHemispherx Biopharma (NYSE:HEB) says rintatolimod European EAP designed has been extended to pancreatic ... - KC Register (NYSE:HEB)
www.kcregister.com - January 14 at 5:39 PM
News IconCurious Trading Activity Sighted in Shares of Hemispherx Biopharma, Inc. (:HEB) - Wall Street Beacon (NYSE:HEB)
wsbeacon.com - January 13 at 6:50 PM
News IconAre Cagey Traders Interested in These Shares: Hemispherx ... - Prospect Journal (NYSE:HEB)
prospectjournal.com - January 12 at 11:07 PM
smarteranalyst.com logoCompany Update (NYSEMKT:HEB): Here Why Shares of Hemispherx BioPharma, Inc Rose 9% (NYSE:HEB)
www.smarteranalyst.com - January 11 at 6:14 PM
finance.yahoo.com logoHemispherx Biopharma Announces Extension of Rintatolimod European Early Access Program (EAP) to Pancreatic Cancer Patients (NYSE:HEB)
finance.yahoo.com - January 11 at 6:14 PM
News IconUnder the Microscope We Place Shares of Hemispherx Biopharma, Inc. (:HEB) - Prospect Journal (NYSE:HEB)
prospectjournal.com - January 11 at 4:38 AM
News IconLevels in View for Hemispherx Biopharma, Inc. (AMEX:HEB) - Wall Street Beacon (NYSE:HEB)
wsbeacon.com - January 11 at 4:38 AM
News IconPrimed for Breakout or Bust? A look at Hemispherx Biopharma, Inc. (:HEB) - Prospect Journal (NYSE:HEB)
prospectjournal.com - January 9 at 11:23 PM
News IconHemispherx Biopharma Inc HEB Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NYSE:HEB)
www.bioportfolio.com - January 5 at 6:38 PM
benzinga.com logoHemispherx BioPharma CEO Talks Stock Performance, Financials And Partnerships (NYSE:HEB)
www.benzinga.com - January 4 at 6:42 PM
News IconHoning in on Shares of Hemispherx Biopharma, Inc. (:HEB) - Prospect Journal (NYSE:HEB)
prospectjournal.com - January 3 at 8:20 PM
benzinga.com logoHemispherx BioPharma CEO Talks About Ampligen, Alferon's Potential - Benzinga (NYSE:HEB)
www.benzinga.com - January 3 at 8:20 PM
capitalcube.com logoETFs with exposure to Hemispherx Biopharma, Inc. : January 3, 2017 (NYSE:HEB)
www.capitalcube.com - January 3 at 8:20 PM
feeds.benzinga.com logoHemispherx BioPharma CEO Talks About Ampligen, Alferon's Potential (NYSE:HEB)
feeds.benzinga.com - January 3 at 3:52 PM

Social

What is Hemispherx BioPharma's stock symbol?

Hemispherx BioPharma trades on the New York Stock Exchange (NYSE) under the ticker symbol "HEB."

When will Hemispherx BioPharma announce their earnings?

Hemispherx BioPharma is scheduled to release their next quarterly earnings announcement on Monday, March, 27th 2017.

How do I buy Hemispherx BioPharma stock?

Shares of Hemispherx BioPharma can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Hemispherx BioPharma stock cost?

One share of Hemispherx BioPharma stock can currently be purchased for approximately $0.48.

Hemispherx BioPharma (NYSE:HEB) Chart for Wednesday, March, 1, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Hemispherx BioPharma (NYSE:HEB)

Earnings History Chart

Earnings by Quarter for Hemispherx BioPharma (NYSE:HEB)

Dividend History Chart

Dividend Payments by Quarter for Hemispherx BioPharma (NYSE:HEB)

Last Updated on 3/1/2017 by MarketBeat.com Staff